

Irene M Lang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7413011/publications.pdf>

Version: 2024-02-01

397
papers

40,397
citations

7087

78
h-index

2825

191
g-index

421
all docs

421
docs citations

421
times ranked

27030
citing authors

#	ARTICLE	IF	CITATIONS
1	2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. European Heart Journal, 2016, 37, 67-119.	1.0	5,074
2	Guidelines on the diagnosis and management of acute pulmonary embolism. European Heart Journal, 2008, 29, 2276-2315.	1.0	2,645
3	2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism. European Heart Journal, 2014, 35, 3033-3080.	1.0	2,591
4	2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. European Respiratory Journal, 2015, 46, 903-975.	3.1	2,415
5	Cellular and molecular pathobiology of pulmonary arterial hypertension. Journal of the American College of Cardiology, 2004, 43, S13-S24.	1.2	1,322
6	Fibrinolysis for Patients with Intermediate-Risk Pulmonary Embolism. New England Journal of Medicine, 2014, 370, 1402-1411.	13.9	1,221
7	Predictors of Outcome in Severe, Asymptomatic Aortic Stenosis. New England Journal of Medicine, 2000, 343, 611-617.	13.9	1,181
8	2020 ESC Guidelines for the management of adult congenital heart disease. European Heart Journal, 2021, 42, 563-645.	1.0	971
9	Chronic Thromboembolic Pulmonary Hypertension (CTEPH). Circulation, 2011, 124, 1973-1981.	1.6	860
10	Selexipag for the Treatment of Pulmonary Arterial Hypertension. New England Journal of Medicine, 2015, 373, 2522-2533.	13.9	790
11	2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Europace, 2015, 17, euv319.	0.7	635
12	Surgical management and outcome of patients with chronic thromboembolic pulmonary hypertension: Results from an international prospective registry. Journal of Thoracic and Cardiovascular Surgery, 2011, 141, 702-710.	0.4	605
13	Bosentan for Treatment of Inoperable Chronic Thromboembolic Pulmonary Hypertension. Journal of the American College of Cardiology, 2008, 52, 2127-2134.	1.2	506
14	Long-Term Outcome of Patients With Chronic Thromboembolic Pulmonary Hypertension. Circulation, 2016, 133, 859-871.	1.6	506
15	Chronic Thromboembolic Pulmonary Hypertension. Journal of the American College of Cardiology, 2013, 62, D92-D99.	1.2	503
16	Pulmonary hypertension due to left heart disease. European Respiratory Journal, 2019, 53, 1801897.	3.1	389
17	Coronary Neutrophil Extracellular Trap Burden and Deoxyribonuclease Activity in ST-Elevation Acute Coronary Syndrome Are Predictors of ST-Segment Resolution and Infarct Size. Circulation Research, 2015, 116, 1182-1192.	2.0	373
18	Risk factors and basic mechanisms of chronic thromboembolic pulmonary hypertension: a current understanding. European Respiratory Journal, 2013, 41, 462-468.	3.1	361

#	ARTICLE	IF	CITATIONS
19	Diagnosis, Assessment, and Treatment of Non-Pulmonary Arterial Hypertension Pulmonary Hypertension. <i>Journal of the American College of Cardiology</i> , 2009, 54, S85-S96.	1.2	353
20	Diastolic Pulmonary Vascular Pressure Gradient. <i>Chest</i> , 2013, 143, 758-766.	0.4	334
21	Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel. <i>American Heart Journal</i> , 2009, 157, 148.e1-148.e5.	1.2	313
22	Mechanisms Underlying Aortic Dilatation in Congenital Aortic Valve Malformation. <i>Circulation</i> , 1999, 99, 2138-2143.	1.6	290
23	ERS statement on chronic thromboembolic pulmonary hypertension. <i>European Respiratory Journal</i> , 2021, 57, 2002828.	3.1	287
24	Selexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2012, 40, 874-880.	3.1	267
25	Predictors of Outcome in Chronic Thromboembolic Pulmonary Hypertension. <i>Circulation</i> , 2007, 115, 2153-2158.	1.6	263
26	Refining the prognostic impact of functional mitral regurgitation in chronic heart failure. <i>European Heart Journal</i> , 2018, 39, 39-46.	1.0	261
27	Impact of Thrombolytic Therapy on the Long-Term Outcome of Intermediate-Risk Pulmonary Embolism. <i>Journal of the American College of Cardiology</i> , 2017, 69, 1536-1544.	1.2	258
28	Medical conditions increasing the risk of chronic thromboembolic pulmonary hypertension. <i>Thrombosis and Haemostasis</i> , 2005, 93, 512-516.	1.8	253
29	Update on Chronic Thromboembolic Pulmonary Hypertension. <i>Circulation</i> , 2014, 130, 508-518.	1.6	249
30	Calcium-Channel Blockers Reduce the Antiplatelet Effect of Clopidogrel. <i>Journal of the American College of Cardiology</i> , 2008, 52, 1557-1563.	1.2	240
31	A transcatheter intracardiac shunt device for heart failure with preserved ejection fraction (REDUCE) Tj ETQq1 1 0.784314 rgBT /Over 6.3 238		
32	Interventional and Surgical Modalities of Treatment in Pulmonary Hypertension. <i>Journal of the American College of Cardiology</i> , 2009, 54, S67-S77.	1.2	230
33	High prevalence of elevated clotting factor VIII in chronic thromboembolic pulmonary hypertension. <i>Thrombosis and Haemostasis</i> , 2003, 90, 372-376.	1.8	221
34	Pulmonary Hypertension in Heart Failure. Epidemiology, Right Ventricular Function, and Survival. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2015, 192, 1234-1246.	2.5	217
35	Acute Hemodynamic Effects of Riociguat in Patients With Pulmonary Hypertension Associated With Diastolic Heart Failure (DILATE-1). <i>Chest</i> , 2014, 146, 1274-1285.	0.4	214
36	Chronic Thromboembolic Pulmonary Hypertension "Not So Rare after All. <i>New England Journal of Medicine</i> , 2004, 350, 2236-2238.	13.9	211

#	ARTICLE	IF	CITATIONS
37	Rapid Endovascular Catheter Core Cooling Combined With Cold Saline as an Adjunct to Percutaneous Coronary Intervention for the Treatment of Acute Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2014, 63, 1857-1865.	1.2	203
38	Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT-1): results from the multicentre, phase 2, randomised, double-blind, placebo-controlled study. <i>Lancet Respiratory Medicine</i> , 2017, 5, 785-794.	5.2	201
39	Interventional and surgical modalities of treatment for pulmonary arterial hypertension. <i>Journal of the American College of Cardiology</i> , 2004, 43, S73-S80.	1.2	194
40	Efficacy of Long-term Subcutaneous Treprostinil Sodium Therapy in Pulmonary Hypertension. <i>Chest</i> , 2006, 129, 1636-1643.	0.4	189
41	Effect of Alirocumab Added to High-Intensity Statin Therapy on Coronary Atherosclerosis in Patients With Acute Myocardial Infarction. <i>JAMA - Journal of the American Medical Association</i> , 2022, 327, 1771.	3.8	185
42	Balloon pulmonary angioplasty in chronic thromboembolic pulmonary hypertension. <i>European Respiratory Review</i> , 2017, 26, 160119.	3.0	183
43	X-Sizer for Thrombectomy in Acute Myocardial Infarction Improves ST-Segment Resolution. <i>Journal of the American College of Cardiology</i> , 2005, 46, 246-252.	1.2	181
44	Intracoronary Thrombectomy With the X-Sizer Catheter System Improves Epicardial Flow and Accelerates ST-Segment Resolution in Patients With Acute Coronary Syndrome. <i>Circulation</i> , 2002, 105, 2355-2360.	1.6	168
45	T1 Mapping by CMR Imaging. <i>JACC: Cardiovascular Imaging</i> , 2016, 9, 14-23.	2.3	164
46	Cardiac Magnetic Resonance Postcontrast T1 Time Is Associated With Outcome in Patients With Heart Failure and Preserved Ejection Fraction. <i>Circulation: Cardiovascular Imaging</i> , 2013, 6, 1056-1065.	1.3	145
47	Edoxaban versus Vitamin K Antagonist for Atrial Fibrillation after TAVR. <i>New England Journal of Medicine</i> , 2021, 385, 2150-2160.	13.9	144
48	Chronic thromboembolic pulmonary hypertension (CTEPH): Updated Recommendations from the Cologne Consensus Conference 2018. <i>International Journal of Cardiology</i> , 2018, 272, 69-78.	0.8	140
49	Effects of Sex and Age on Growth Hormone Response to Growth Hormone-Releasing Hormone in Healthy Individuals. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1987, 65, 535-540.	1.8	138
50	Bosentan Therapy for Inoperable Chronic Thromboembolic Pulmonary Hypertension. <i>Chest</i> , 2005, 128, 2599-2603.	0.4	129
51	Coronary no-reflow is caused by shedding of active tissue factor from dissected atherosclerotic plaque. <i>Blood</i> , 2002, 99, 2794-2800.	0.6	126
52	The Pathobiology of Chronic Thromboembolic Pulmonary Hypertension. <i>Annals of the American Thoracic Society</i> , 2016, 13, S215-S221.	1.5	121
53	Combined delivery approach of bone marrow mononuclear stem cells early and late after myocardial infarction: the MYSTAR prospective, randomized study. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2009, 6, 70-81.	3.3	118
54	ESC Joint Working Groups on Cardiovascular Surgery and the Cellular Biology of the Heart Position Paper: Peri-operative myocardial injury and infarction in patients undergoing coronary artery bypass graft surgery. <i>European Heart Journal</i> , 2017, 38, 2392-2411.	1.0	118

#	ARTICLE	IF	CITATIONS
55	Subcutaneous treprostinil for the treatment of severe non-operable chronic thromboembolic pulmonary hypertension (CTREPH): a double-blind, phase 3, randomised controlled trial. <i>Lancet Respiratory Medicine</i> , 2019, 7, 239-248.	5.2	116
56	Chronic heart failure leads to an expanded plasma volume and pseudoanaemia, but does not lead to a reduction in the body's red cell volume. <i>European Heart Journal</i> , 2008, 29, 2343-2350.	1.0	113
57	Left Ventricular Diastolic Dysfunction in Patients With COPD in the Presence and Absence of Elevated Pulmonary Arterial Pressure. <i>Chest</i> , 2008, 133, 1354-1359.	0.4	107
58	Local complement activation triggers neutrophil recruitment to the site of thrombus formation in acute myocardial infarction. <i>Thrombosis and Haemostasis</i> , 2009, 102, 564-572.	1.8	103
59	Role for Staphylococci in Misguided Thrombus Resolution of Chronic Thromboembolic Pulmonary Hypertension. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2008, 28, 678-684.	1.1	100
60	Vascular and right ventricular remodelling in chronic thromboembolic pulmonary hypertension. <i>European Respiratory Journal</i> , 2013, 41, 224-232.	3.1	100
61	Asymmetric Dimethylarginine Is Increased in Chronic Thromboembolic Pulmonary Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2007, 176, 1154-1160.	2.5	98
62	Selexipag for the treatment of connective tissue disease-associated pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2017, 50, 1602493.	3.1	97
63	Factors associated with diagnosis and operability of chronic thromboembolic pulmonary hypertension. <i>Thrombosis and Haemostasis</i> , 2013, 110, 83-91.	1.8	96
64	Circulating microparticles carry oxidation-specific epitopes and are recognized by natural IgM antibodies. <i>Journal of Lipid Research</i> , 2015, 56, 440-448.	2.0	96
65	Defective Angiogenesis Delays Thrombus Resolution. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2014, 34, 810-819.	1.1	95
66	Lung transplantation for idiopathic pulmonary arterial hypertension on intraoperative and postoperatively prolonged extracorporeal membrane oxygenation provides optimally controlled reperfusion and excellent outcome. <i>European Journal of Cardio-thoracic Surgery</i> , 2018, 53, 178-185.	0.6	95
67	Frequency, risk factors, and impact on mortality of arterial thromboembolism in patients with cancer. <i>Haematologica</i> , 2018, 103, 1549-1556.	1.7	95
68	Interleukin 8 (IL-8) - a universal biomarker?. <i>International Archive of Medicine</i> , 2010, 3, 11.	1.2	94
69	Comprehensive analysis of inflammatory markers in chronic thromboembolic pulmonary hypertension patients. <i>European Respiratory Journal</i> , 2014, 44, 951-962.	3.1	94
70	Chronic thromboembolic pulmonary hypertension (CTEPH): Updated Recommendations of the Cologne Consensus Conference 2011. <i>International Journal of Cardiology</i> , 2011, 154, S54-S60.	0.8	93
71	Association of PCSK9 with platelet reactivity in patients with acute coronary syndrome treated with prasugrel or ticagrelor: The PCSK9-REACT study. <i>International Journal of Cardiology</i> , 2017, 227, 644-649.	0.8	91
72	Combination Therapy with Oral Treprostinil for Pulmonary Arterial Hypertension. A Double-Blind Placebo-controlled Clinical Trial. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 201, 707-717.	2.5	89

#	ARTICLE	IF	CITATIONS
73	Chronic thromboembolic pulmonary hypertension: a distinct disease entity. <i>European Respiratory Review</i> , 2015, 24, 246-252.	3.0	84
74	Hemodynamic Phenotyping of Pulmonary Hypertension in Left Heart Failure. <i>Circulation: Heart Failure</i> , 2017, 10, .	1.6	84
75	Pulmonary hypertension in heart failure with preserved ejection fraction: a plea for proper phenotyping and further research. <i>European Heart Journal</i> , 2017, 38, ehw597.	1.0	83
76	Optimal follow-up after acute pulmonary embolism: a position paper of the European Society of Cardiology Working Group on Pulmonary Circulation and Right Ventricular Function, in collaboration with the European Society of Cardiology Working Group on Atherosclerosis and Vascular Biology, endorsed by the European Respiratory Society. <i>European Heart Journal</i> , 2022, 43, 183-189.	1.0	83
77	Right Ventricular Load at Exercise Is a Cause of Persistent Exercise Limitation in Patients With Normal Resting Pulmonary Vascular Resistance After Pulmonary Endarterectomy. <i>Chest</i> , 2011, 139, 122-127.	0.4	82
78	Pulmonary Arterial Hypertension-Related Morbidity Is Prognostic for Mortality. <i>Journal of the American College of Cardiology</i> , 2018, 71, 752-763.	1.2	82
79	Citrullinated histone H3, a biomarker for neutrophil extracellular trap formation, predicts the risk of mortality in patients with cancer. <i>British Journal of Haematology</i> , 2019, 186, 311-320.	1.2	82
80	Light chain and transthyretin cardiac amyloidosis in severe aortic stenosis: prevalence, screening possibilities, and outcome. <i>European Journal of Heart Failure</i> , 2020, 22, 1852-1862.	2.9	82
81	Pulmonary Vascular Reactivity and Prognosis in Patients With Chronic Thromboembolic Pulmonary Hypertension. <i>Circulation</i> , 2009, 119, 298-305.	1.6	81
82	Phenotyping vs. genotyping for prediction of clopidogrel efficacy and safety: the PEGASUS-PCI study. <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 529-542.	1.9	81
83	Prognostic factors associated with increased survival in patients with pulmonary arterial hypertension treated with subcutaneous treprostinil in randomized, placebo-controlled trials. <i>Journal of Heart and Lung Transplantation</i> , 2011, 30, 982-989.	0.3	80
84	The Impact of Post-Procedural Asymmetry, Expansion, and Eccentricity of Bioresorbable Everolimus-Eluting Scaffold and Metallic Everolimus-Eluting Stent on Clinical Outcomes in the ABSORB II Trial. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 1231-1242.	1.1	80
85	Prognostic value of plasma midregional proadrenomedullin and C-terminal endothelin-1 in chronic heart failure outpatients. <i>European Journal of Heart Failure</i> , 2009, 11, 361-366.	2.9	78
86	Recent advances in targeting the prostacyclin pathway in pulmonary arterial hypertension. <i>European Respiratory Review</i> , 2015, 24, 630-641.	3.0	78
87	Determinants of diagnostic delay in chronic thromboembolic pulmonary hypertension: results from the European CTEPH Registry. <i>European Respiratory Journal</i> , 2018, 52, 1801687.	3.1	78
88	Imaging in Pulmonary Hypertension. <i>JACC: Cardiovascular Imaging</i> , 2010, 3, 1287-1295.	2.3	72
89	Neutrophil extracellular traps promote fibrous vascular occlusions in chronic thrombosis. <i>Blood</i> , 2021, 137, 1104-1116.	0.6	71
90	Chronic thromboembolic pulmonary hypertension: an updated review. <i>Current Opinion in Cardiology</i> , 2008, 23, 555-559.	0.8	69

#	ARTICLE	IF	CITATIONS
91	Targeting the Prostacyclin Pathway with Selexipag in Patients with Pulmonary Arterial Hypertension Receiving Double Combination Therapy: Insights from the Randomized Controlled GRIPHON Study. <i>American Journal of Cardiovascular Drugs</i> , 2018, 18, 37-47.	1.0	69
92	A Decrease in Plasminogen Activator Inhibitor-1 Activity after Successful Percutaneous Transluminal Coronary Angioplasty Is Associated with a Significantly Reduced Risk for Coronary Restenosis. <i>Thrombosis and Haemostasis</i> , 1992, 67, 209-213.	1.8	68
93	Association of N-Terminal Pro Brain Natriuretic Peptide and Long-Term Outcome in Patients With Pulmonary Arterial Hypertension. <i>Circulation</i> , 2019, 139, 2440-2450.	1.6	67
94	Risk Factors for Chronic Thromboembolic Pulmonary Hypertension. <i>Proceedings of the American Thoracic Society</i> , 2006, 3, 568-570.	3.5	66
95	Current strategies for managing chronic thromboembolic pulmonary hypertension: results of the worldwide prospective CTEPH Registry. <i>ERJ Open Research</i> , 2021, 7, 00850-2020.	1.1	65
96	Role of adult bone marrow stem cells in the repair of ischemic myocardium: Current state of the art. <i>Experimental Hematology</i> , 2008, 36, 672-680.	0.2	63
97	Loss of high-molecular-weight von Willebrand factor multimers mainly affects platelet aggregation in patients with aortic stenosis. <i>Thrombosis and Haemostasis</i> , 2010, 103, 408-414.	1.8	62
98	Relative risk of arterial and venous thromboembolism in persons with cancer vs. persons without cancer—a nationwide analysis. <i>European Heart Journal</i> , 2021, 42, 2299-2307.	1.0	62
99	Effect of radio contrast media on residual renal function in peritoneal dialysis patients—a prospective study. <i>Nephrology Dialysis Transplantation</i> , 2006, 21, 1334-1339.	0.4	60
100	Neutrophil extracellular traps and fibrocytes in ST-segment elevation myocardial infarction. <i>Basic Research in Cardiology</i> , 2019, 114, 33.	2.5	60
101	Evolution of outcome and complications in TAVR: a meta-analysis of observational and randomized studies. <i>Scientific Reports</i> , 2020, 10, 15568.	1.6	60
102	Vascular morphogenesis by adult bone marrow progenitor cells in three-dimensional fibrin matrices. <i>Differentiation</i> , 2008, 76, 772-783.	1.0	59
103	Beneficial effects of levosimendan on survival in patients undergoing extracorporeal membrane oxygenation after cardiovascular surgery. <i>British Journal of Anaesthesia</i> , 2016, 117, 52-58.	1.5	59
104	Systematic primary aspiration in acute myocardial percutaneous intervention: a multicentre randomised controlled trial of the export aspiration catheter. <i>EuroIntervention</i> , 2008, 4, 222-228.	1.4	59
105	Ultrasound-facilitated, catheter-directed thrombolysis vs anticoagulation alone for acute intermediate-high-risk pulmonary embolism: Rationale and design of the HI-PEITHO study. <i>American Heart Journal</i> , 2022, 251, 43-53.	1.2	59
106	Splenectomy Is Modifying the Vascular Remodeling of Thrombosis. <i>Journal of the American Heart Association</i> , 2014, 3, e000772.	1.6	58
107	The Adult Patient with Eisenmenger Syndrome: A Medical Update After Dana Point Part I: Epidemiology, Clinical Aspects and Diagnostic Options. <i>Current Cardiology Reviews</i> , 2010, 6, 343-355.	0.6	56
108	Pulmonary hypertension associated with left heart disease: Updated Recommendations of the Cologne Consensus Conference 2018. <i>International Journal of Cardiology</i> , 2018, 272, 53-62.	0.8	56

#	ARTICLE	IF	CITATIONS
109	Angiostatic Factors in the Pulmonary Endarterectomy Material from Chronic Thromboembolic Pulmonary Hypertension Patients Cause Endothelial Dysfunction. <i>PLoS ONE</i> , 2012, 7, e43793.	1.1	55
110	Quantitative assessment of human serum high-abundance protein depletion. <i>Electrophoresis</i> , 2008, 29, 4316-4323.	1.3	54
111	Therapeutic Hypothermia for the Treatment of Acute Myocardial Infarction—Combined Analysis of the RAPID MI-ICE and the CHILL-MI Trials. <i>Therapeutic Hypothermia and Temperature Management</i> , 2015, 5, 77-84.	0.3	54
112	From thrombosis to fibrosis in chronic thromboembolic pulmonary hypertension. <i>Thrombosis and Haemostasis</i> , 2017, 117, 769-783.	1.8	53
113	Echocardiographic assessment of right ventricular function: current clinical practice. <i>International Journal of Cardiovascular Imaging</i> , 2019, 35, 49-56.	0.7	53
114	Arterial Remodeling After Bioresorbable Scaffolds and Metallic Stents. <i>Journal of the American College of Cardiology</i> , 2017, 70, 60-74.	1.2	51
115	Microvascular Disease in Chronic Thromboembolic Pulmonary Hypertension. <i>Circulation</i> , 2020, 141, 376-386.	1.6	51
116	Recombinant rabbit Fab with binding activity to type-1 plasminogen activator inhibitor derived from a phage-display library against human α_2 -granules. <i>Gene</i> , 1996, 172, 295-298.	1.0	49
117	Pulmonary Artery Thromboendarterectomy: A Comparison of Two Different Postoperative Treatment Strategies. <i>Anesthesia and Analgesia</i> , 2000, 90, 267.	1.1	48
118	Current and Future Management of Chronic Thromboembolic Pulmonary Hypertension: From Diagnosis to Treatment Responses. <i>Proceedings of the American Thoracic Society</i> , 2006, 3, 601-607.	3.5	48
119	Design and rationale for the Myocardial Stem Cell Administration After Acute Myocardial Infarction (MYSTAR) Study: A multicenter, prospective, randomized, single-blind trial comparing early and late intracoronary or combined (percutaneous intramyocardial and intracoronary) administration of nonselected autologous bone marrow cells to patients after acute myocardial infarction. <i>American Heart Journal</i> , 2007, 153, 212.e1-212.e7.	1.2	48
120	The Adult Patient with Eisenmenger Syndrome: A Medical Update after Dana Point Part III: Specific Management and Surgical Aspects. <i>Current Cardiology Reviews</i> , 2010, 6, 363-372.	0.6	48
121	Prognostic Significance and Determinants of the 6-Min Walk Test in Patients With Heart Failure and Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2015, 3, 459-466.	1.9	48
122	Chronic complications of venous thromboembolism. <i>Journal of Thrombosis and Haemostasis</i> , 2017, 15, 1531-1540.	1.9	48
123	Aerosolized Iloprost Therapy Could Not Replace Long-term IV Epoprostenol (Prostacyclin) Administration in Severe Pulmonary Hypertension. <i>Chest</i> , 2001, 119, 296-300.	0.4	47
124	Intravascular Ultrasound Pulmonary Artery Denervation to Treat Pulmonary Arterial Hypertension (TROPHY1). <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 989-999.	1.1	47
125	Liver function predicts survival in patients undergoing extracorporeal membrane oxygenation following cardiovascular surgery. <i>Critical Care</i> , 2016, 20, 57.	2.5	46
126	Hypertension and coronary artery disease: epidemiology, physiology, effects of treatment, and recommendations. <i>Wiener Klinische Wochenschrift</i> , 2016, 128, 467-479.	1.0	45

#	ARTICLE	IF	CITATIONS
127	Impact of an interatrial shunt device on survival and heart failure hospitalization in patients with preserved ejection fraction. <i>ESC Heart Failure</i> , 2019, 6, 62-69.	1.4	45
128	Long-term treatment, tolerability, and survival with sub-cutaneous treprostinil for severe pulmonary hypertension. <i>Journal of Heart and Lung Transplantation</i> , 2012, 31, 735-743.	0.3	44
129	Platelet endothelial cell adhesion molecule 1 deficiency misguides venous thrombus resolution. <i>Blood</i> , 2013, 122, 3376-3384.	0.6	44
130	Incomplete echocardiographic recovery at 6 months predicts long-term sequelae after intermediate-risk pulmonary embolism. A post-hoc analysis of the Pulmonary Embolism Thrombolysis (PEITHO) trial. <i>Clinical Research in Cardiology</i> , 2019, 108, 772-778.	1.5	44
131	Sex-specific differences in chronic thromboembolic pulmonary hypertension. Results from the European CTEPH registry. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 151-161.	1.9	42
132	Elevated Expression of Urokinase-like Plasminogen Activator and Plasminogen Activator Inhibitor Type 1 During the Vascular Remodeling Associated With Pulmonary Thromboembolism. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1998, 18, 808-815.	1.1	41
133	Accumulation of oxidized LDL in human semilunar valves correlates with coronary atherosclerosis. <i>Cardiovascular Research</i> , 2000, 45, 874-882.	1.8	41
134	Expression of the Angiogenic Protein, Platelet-Derived Endothelial Cell Growth Factor, in Coronary Atherosclerotic Plaques. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1999, 19, 2340-2347.	1.1	40
135	Evolution of secondary mitral regurgitation. <i>European Heart Journal Cardiovascular Imaging</i> , 2018, 19, 622-629.	0.5	40
136	Selexipag treatment for pulmonary arterial hypertension associated with congenital heart disease after defect correction: insights from the randomised controlled GRIPHON study. <i>European Journal of Heart Failure</i> , 2019, 21, 352-359.	2.9	40
137	Left Main Coronary Artery Compression by the Pulmonary Trunk in Pulmonary Hypertension. <i>Circulation</i> , 2002, 105, 265-265.	1.6	39
138	Duration of extracorporeal membrane oxygenation support and survival in cardiovascular surgery patients. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2018, 155, 2471-2476.	0.4	39
139	Risk assessment in pulmonary arterial hypertension: Insights from the GRIPHON study. <i>Journal of Heart and Lung Transplantation</i> , 2020, 39, 300-309.	0.3	39
140	Heart failure subtypes and thromboembolic risk in patients with atrial fibrillation: The PREFER in AF - HF substudy. <i>International Journal of Cardiology</i> , 2018, 265, 141-147.	0.8	38
141	Association of Platelet-to-Lymphocyte Ratio and Neutrophil-to-Lymphocyte Ratio with the Risk of Thromboembolism and Mortality in Patients with Cancer. <i>Thrombosis and Haemostasis</i> , 2018, 118, 1875-1884.	1.8	38
142	Calcium-dependent Stabilization of Type I Plasminogen Activator Inhibitor within Platelet Granules. <i>Journal of Biological Chemistry</i> , 1996, 271, 2754-2761.	1.6	37
143	Mortality in patients resuscitated from out-of-hospital cardiac arrest based on automated blood cell count and neutrophil lymphocyte ratio at admission. <i>Resuscitation</i> , 2017, 116, 49-55.	1.3	37
144	The burden of comorbidities in pulmonary arterial hypertension. <i>European Heart Journal Supplements</i> , 2019, 21, K21-K28.	0.0	37

#	ARTICLE	IF	CITATIONS
145	The effect of antiplatelet drugs clopidogrel and aspirin is less immediately after stent implantation. <i>Thrombosis Research</i> , 2009, 123, 874-880.	0.8	36
146	How to define pulmonary hypertension due to left heart disease. <i>European Respiratory Journal</i> , 2016, 48, 553-555.	3.1	36
147	Evaluation and management of patients with chronic thromboembolic pulmonary hypertension - consensus statement from the ISHLT. <i>Journal of Heart and Lung Transplantation</i> , 2021, 40, 1301-1326.	0.3	36
148	Right Ventricle in Acute and Chronic Pulmonary Embolism (2013 Grover Conference Series). <i>Pulmonary Circulation</i> , 2014, 4, 378-386.	0.8	35
149	No Increased Prevalence of the Factor V Leiden Mutation in Chronic Major Vessel Thromboembolic Pulmonary Hypertension (CTEPH). <i>Thrombosis and Haemostasis</i> , 1996, 76, 476-477.	1.8	35
150	Abnormalities in the Hypothalamic-Pituitary-Adrenocortical Axis in Patients With Chronic Renal Failure. <i>American Journal of Kidney Diseases</i> , 1987, 9, 51-54.	2.1	34
151	Identification of a Novel Exon in Apolipoprotein E Receptor 2 Leading to Alternatively Spliced mRNAs Found in Cells of the Vascular Wall but Not in Neuronal Tissue. <i>Journal of Biological Chemistry</i> , 2001, 276, 13192-13197.	1.6	34
152	Sex Difference in Patients With Ischemic Heart Failure Undergoing Surgical Revascularization. <i>Circulation</i> , 2018, 137, 771-780.	1.6	34
153	Sublingual functional capillary rarefaction in chronic heart failure. <i>European Journal of Clinical Investigation</i> , 2018, 48, e12869.	1.7	34
154	An International Physician Survey of Chronic Thromboembolic Pulmonary Hypertension Management. <i>Pulmonary Circulation</i> , 2016, 6, 472-482.	0.8	33
155	Hemodynamic Thresholds for Precapillary Pulmonary Hypertension. <i>Chest</i> , 2016, 149, 1061-1073.	0.4	33
156	Evaluation of the CT imaging findings in patients newly diagnosed with chronic thromboembolic pulmonary hypertension. <i>PLoS ONE</i> , 2018, 13, e0201468.	1.1	33
157	ELISA detection of MPO-DNA complexes in human plasma is error-prone and yields limited information on neutrophil extracellular traps formed in vivo. <i>PLoS ONE</i> , 2021, 16, e0250265.	1.1	33
158	Active endothelin is an important vasoconstrictor in acute coronary thrombi. <i>Thrombosis and Haemostasis</i> , 2007, 97, 642-649.	1.8	32
159	Atrial septal defect repair after a 10-month treatment with bosentan in a patient with severe pulmonary arterial hypertension: A case report. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2009, 137, 760-761.	0.4	32
160	Advances in understanding the pathogenesis of chronic thromboembolic pulmonary hypertension. <i>British Journal of Haematology</i> , 2010, 149, 478-483.	1.2	32
161	Histone citrullination as a novel biomarker and target to inhibit progression of abdominal aortic aneurysms. <i>Translational Research</i> , 2021, 233, 32-46.	2.2	32
162	A Clinical Comparison of Slow- and Rapid-Escalation Treprostinil Dosing Regimens in Patients with Pulmonary Hypertension. <i>Clinical Pharmacokinetics</i> , 2008, 47, 611-618.	1.6	31

#	ARTICLE	IF	CITATIONS
163	Neutrophil extracellular traps and monocyte subsets at the culprit lesion site of myocardial infarction patients. <i>Scientific Reports</i> , 2019, 9, 16304.	1.6	31
164	Treprostinil for pulmonary hypertension. <i>Vascular Health and Risk Management</i> , 2008, Volume 4, 507-513.	1.0	30
165	Abciximab as a bridging strategy to overcome morphineâ€™prasugrel interaction in STEMI patients. <i>British Journal of Clinical Pharmacology</i> , 2016, 82, 1343-1350.	1.1	30
166	Characteristics and survival data from Latvian pulmonary hypertension registry: comparison of prospective pulmonary hypertension registries in Europe. <i>Pulmonary Circulation</i> , 2018, 8, 1-9.	0.8	30
167	Chronic thromboembolic pulmonary hypertension in Austria and Japan. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2019, 158, 604-614.e2.	0.4	30
168	Residual platelet activation through protease-activated receptors (PAR)-1 and â€™4 in patients on P2Y12 inhibitors. <i>International Journal of Cardiology</i> , 2013, 168, 403-406.	0.8	28
169	Prognostic Significance of Biomarkers in Predicting Outcome in Patients With Coronary Artery Disease and Left Ventricular Dysfunction. <i>Circulation: Heart Failure</i> , 2013, 6, 461-472.	1.6	28
170	Serum butyrylcholinesterase predicts survival after extracorporeal membrane oxygenation after cardiovascular surgery. <i>Critical Care</i> , 2014, 18, R24.	2.5	28
171	Prognostic value of culprit site neutrophils in acute coronary syndrome. <i>European Journal of Clinical Investigation</i> , 2014, 44, 257-265.	1.7	28
172	State-of-the-Art Review: Echocardiography in Pulmonary Hypertension. <i>Heart Lung and Circulation</i> , 2019, 28, 1351-1364.	0.2	28
173	Out-of-hospital initiation of hypothermia in ST-segment elevation myocardial infarction: a randomised trial. <i>Heart</i> , 2019, 105, 531-537.	1.2	28
174	Interruption of vascular endothelial growth factor receptor 2 signaling induces a proliferative pulmonary vasculopathy and pulmonary hypertension. <i>Basic Research in Cardiology</i> , 2020, 115, 58.	2.5	28
175	Efficacy and Safety of Percutaneous Pulmonary Artery Subtotal Occlusion and Chronic Total Occlusion Intervention in Chronic Thromboembolic Pulmonary Hypertension. <i>Circulation: Cardiovascular Interventions</i> , 2021, 14, e010243.	1.4	28
176	Factors Determining Patient-Prosthesis Mismatch after Aortic Valve Replacement â€™ A Prospective Cohort Study. <i>PLoS ONE</i> , 2013, 8, e81940.	1.1	28
177	Prasugrel Reduces Agonistsâ€™ Inducible Platelet Activation and Leukocyteâ€™Platelet Interaction more efficiently than Clopidogrel. <i>Cardiovascular Therapeutics</i> , 2013, 31, e40-5.	1.1	27
178	Distribution of clinical events across platelet aggregation values in all-comers treated with prasugrel and ticagrelor. <i>Vascular Pharmacology</i> , 2016, 79, 6-10.	1.0	27
179	Development and implementation of common data elements for venous thromboembolism research: on behalf of SSC Subcommittee on official Communication from the SSC of the ISTH. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 297-303.	1.9	27
180	Aggressive Afterload Lowering to Improve the Right Ventricle: A New Target for Medical Therapy in Pulmonary Arterial Hypertension?. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, 205, 751-760.	2.5	27

#	ARTICLE	IF	CITATIONS
181	Effect of intramyocardial delivery of autologous bone marrow mononuclear stem cells on the regional myocardial perfusion. <i>Thrombosis and Haemostasis</i> , 2010, 103, 564-571.	1.8	26
182	Results of an Expert Consensus Survey on the Treatment of Pulmonary Arterial Hypertension With Oral Prostacyclin Pathway Agents. <i>Chest</i> , 2020, 157, 955-965.	0.4	26
183	Outcome in Heart Failure with Preserved Ejection Fraction: The Role of Myocardial Structure and Right Ventricular Performance. <i>PLoS ONE</i> , 2015, 10, e0134479.	1.1	26
184	Prothrombotic activation of pulmonary arterial endothelial cells in a patient with tuberculosis. <i>Human Pathology</i> , 1996, 27, 423-427.	1.1	25
185	Managing chronic thromboembolic pulmonary hypertension: pharmacological treatment options. <i>European Respiratory Review</i> , 2009, 18, 24-28.	3.0	25
186	Selexipag for the treatment of pulmonary arterial hypertension. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 429-436.	0.9	25
187	Interaction of factor VII activating protease (FSAP) with neutrophil extracellular traps (NETs). <i>Thrombosis Research</i> , 2018, 161, 36-42.	0.8	25
188	Association of complete blood count parameters, dâ€dimer, and soluble Pâ€selectin with risk of arterial thromboembolism in patients with cancer. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 1335-1344.	1.9	25
189	Inter-patient variability of platelet reactivity in patients treated with prasugrel and ticagrelor. <i>Platelets</i> , 2016, 27, 373-377.	1.1	24
190	Impact of Routine Invasive Physiology atÂTime of Angiography in Patients WithÂMultivessel Coronary Artery DiseaseÂon Reclassification of Revascularization Strategy. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 354-365.	1.1	24
191	Platelet reactivity patterns in patients treated with dual antiplatelet therapy. <i>European Journal of Clinical Investigation</i> , 2019, 49, e13102.	1.7	24
192	Geographical miss during intracoronary irradiation: impact on restenosis and determination of required safety margin length. <i>Journal of the American College of Cardiology</i> , 2002, 40, 1225-1231.	1.2	23
193	Longitudinal analysis of perfusion lung scintigrams of patients with unoperated chronic thromboembolic pulmonary hypertension. <i>Thrombosis and Haemostasis</i> , 2004, 92, 201-207.	1.8	23
194	Interplay between Genetic and Clinical Variables Affecting Platelet Reactivity and Cardiac Adverse Events in Patients Undergoing Percutaneous Coronary Intervention. <i>PLoS ONE</i> , 2014, 9, e102701.	1.1	23
195	Soluble galectinâ€3 is associated with premature myocardial infarction. <i>European Journal of Clinical Investigation</i> , 2016, 46, 386-391.	1.7	23
196	Riociguat in patients with chronic thromboembolic pulmonary hypertension: results from an early access study. <i>BMC Pulmonary Medicine</i> , 2017, 17, 216.	0.8	23
197	Current understanding of the pathophysiology of chronic thromboembolic pulmonary hypertension. <i>Thrombosis Research</i> , 2018, 164, 136-144.	0.8	23
198	Visual assessment of right ventricular function by echocardiography: how good are we?. <i>International Journal of Cardiovascular Imaging</i> , 2019, 35, 2001-2008.	0.7	23

#	ARTICLE	IF	CITATIONS
199	Riociguat treatment in patients with chronic thromboembolic pulmonary hypertension: Final safety data from the EXPERT registry. <i>Respiratory Medicine</i> , 2021, 178, 106220.	1.3	23
200	Local and Systemic RAGE Axis Changes in Pulmonary Hypertension: CTEPH and iPAH. <i>PLoS ONE</i> , 2014, 9, e106440.	1.1	23
201	A novel therapeutic strategy for the management of idiopathic chylopericardium and chylothorax. <i>Surgery</i> , 1998, 123, 369-370.	1.0	22
202	Coagulation and the Vessel Wall in Pulmonary Embolism. <i>Pulmonary Circulation</i> , 2013, 3, 728-738.	0.8	22
203	Impact of surgical ventricular reconstruction on sphericity index in patients with ischaemic cardiomyopathy: follow-up from the <sc>STICH</sc> trial. <i>European Journal of Heart Failure</i> , 2015, 17, 453-463.	2.9	22
204	Cardiac arrest does not affect survival in post-operative cardiovascular surgery patients undergoing extracorporeal membrane oxygenation. <i>Resuscitation</i> , 2016, 104, 24-27.	1.3	22
205	The impact of comorbidities on selexipag treatment effect in patients with pulmonary arterial hypertension: insights from the <sc>GRIPHON</sc> study. <i>European Journal of Heart Failure</i> , 2022, 24, 205-214.	2.9	22
206	Impairment of the Plasmin Activation System in Primary Pulmonary Hypertension: Evidence for Gender Differences. <i>Thrombosis and Haemostasis</i> , 2001, 86, 557-562.	1.8	21
207	Impaired antioxidant HDL function is associated with premature myocardial infarction. <i>European Journal of Clinical Investigation</i> , 2015, 45, 731-738.	1.7	21
208	Sudden Cardiac Death in Patients With Ischemic Heart Failure Undergoing Coronary Artery Bypass Grafting. <i>Circulation</i> , 2017, 135, 1136-1144.	1.6	21
209	Distinguishing Chronic Thromboembolic Pulmonary Hypertension From Other Causes of Pulmonary Hypertension Using CT. <i>American Journal of Roentgenology</i> , 2017, 209, 1228-1238.	1.0	21
210	Functional capillary impairment in patients with ventricular assist devices. <i>Scientific Reports</i> , 2019, 9, 5909.	1.6	21
211	Sex-Based Outcomes in Patients With a High Bleeding Risk After Percutaneous Coronary Intervention and 1-Month Dual Antiplatelet Therapy. <i>JAMA Cardiology</i> , 2020, 5, 939.	3.0	21
212	Relationship Between Time From Diagnosis and Morbidity/Mortality in Pulmonary Arterial Hypertension. <i>Chest</i> , 2021, 160, 277-286.	0.4	21
213	Fibrinolytic Balance of the Arterial Wall: Pulmonary Artery Displays Increased Fibrinolytic Potential Compared with Aorta. <i>Laboratory Investigation</i> , 2003, 83, 871-876.	1.7	20
214	Urinary Output Predicts Survival in Patients Undergoing Extracorporeal Membrane Oxygenation Following Cardiovascular Surgery. <i>Critical Care Medicine</i> , 2016, 44, 531-538.	0.4	20
215	Evaluation of the pharmacoDYNAMIC effects of riociguat in subjects with pulmonary hypertension and heart failure with preserved ejection fraction. <i>Wiener Klinische Wochenschrift</i> , 2016, 128, 882-889.	1.0	20
216	Ambrisentan for treatment of inoperable chronic thromboembolic pulmonary hypertension (CTEPH). <i>Pulmonary Circulation</i> , 2019, 9, 1-3.	0.8	20

#	ARTICLE	IF	CITATIONS
217	Neutrophil Extracellular Traps Induce MCP-1 at the Culprit Site in ST-Segment Elevation Myocardial Infarction. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 564169.	1.8	20
218	Nonculprit Lesion Severity and Outcome of Revascularization in Patients With STEMI and Multivessel Coronary Disease. <i>Journal of the American College of Cardiology</i> , 2020, 76, 1277-1286.	1.2	20
219	Ticagrelor Inhibits Toll-Like and Protease-Activated Receptor Mediated Platelet Activation in Acute Coronary Syndromes. <i>Cardiovascular Drugs and Therapy</i> , 2020, 34, 53-63.	1.3	20
220	Chronic Thromboembolic Disease and Chronic Thromboembolic Pulmonary Hypertension. <i>Clinics in Chest Medicine</i> , 2021, 42, 81-90.	0.8	20
221	Vasoactive intestinal peptide gene alterations in patients with idiopathic pulmonary arterial hypertension. <i>European Journal of Human Genetics</i> , 2007, 15, 18-22.	1.4	19
222	Regulation of PAR-1 in patients undergoing percutaneous coronary intervention: effects of unfractionated heparin and bivalirudin. <i>European Heart Journal</i> , 2009, 30, 1831-1836.	1.0	19
223	Impaired High-Density Lipoprotein Anti-Oxidative Function Is Associated With Outcome in Patients With Chronic Heart Failure. <i>Journal of the American Heart Association</i> , 2016, 5, .	1.6	19
224	Clusterin/apolipoprotein J is independently associated with survival in patients with chronic heart failure. <i>Journal of Clinical Lipidology</i> , 2017, 11, 178-184.	0.6	19
225	Acquired nintedanib resistance in FGFR1-driven small cell lung cancer: role of endothelin-A receptor-activated ABCB1 expression. <i>Oncotarget</i> , 2016, 7, 50161-50179.	0.8	19
226	In-depth haemodynamic phenotyping of pulmonary hypertension due to left heart disease. <i>European Respiratory Journal</i> , 2018, 51, 1800067.	3.1	18
227	Lipid profile and long-term outcome in premature myocardial infarction. <i>European Journal of Clinical Investigation</i> , 2018, 48, e13008.	1.7	18
228	Protease-activated receptor-mediated platelet aggregation in acute coronary syndrome patients on potent P2Y12 inhibitors. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2019, 3, 383-390.	1.0	18
229	Interleukin-6 level is a powerful predictor of long-term cardiovascular mortality in patients with acute coronary syndrome. <i>Vascular Pharmacology</i> , 2020, 135, 106806.	1.0	18
230	Systemic endothelin receptor blockade in ST-segment elevation acute coronary syndrome protects the microvasculature: a randomised pilot study. <i>EuroIntervention</i> , 2012, 7, 1386-1395.	1.4	18
231	Treprostinil for the treatment of pulmonary hypertension. <i>Expert Opinion on Pharmacotherapy</i> , 2008, 9, 1415-1420.	0.9	17
232	Long-term mortality in patients with chronic obstructive pulmonary disease following extracorporeal membrane oxygenation for cardiac assist after cardiovascular surgery. <i>Intensive Care Medicine</i> , 2013, 39, 1444-1451.	3.9	17
233	Characterization of Pulmonary Hypertension in Heart Failure Using the Diastolic Pressure Gradient. <i>JACC: Heart Failure</i> , 2015, 3, 424-425.	1.9	17
234	Effects of the PCSK9 antibody alirocumab on coronary atherosclerosis in patients with acute myocardial infarction: a serial, multivessel, intravascular ultrasound, near-infrared spectroscopy and optical coherence tomography imaging studyâ€“Rationale and design of the PACMAN-AMI trial. <i>American Heart Journal</i> , 2021, 238, 33-44.	1.2	17

#	ARTICLE	IF	CITATIONS
235	<i>In vivo</i> relationship between near-infrared spectroscopy-detected lipid-rich plaques and morphological plaque characteristics by optical coherence tomography and intravascular ultrasound: a multimodality intravascular imaging study. <i>European Heart Journal Cardiovascular Imaging</i> , 2021, 22, 824-834.	0.5	17
236	Tadalafil for the treatment of pulmonary arterial hypertension. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, 747-755.	0.9	16
237	Decreased platelet inhibition by P2Y12 receptor blockers in anaemia. <i>European Journal of Clinical Investigation</i> , 2018, 48, e12861.	1.7	16
238	Comparison of MRI and VQ-SPECT as a Screening Test for Patients With Suspected CTEPH: CHANGE-MRI Study Design and Rationale. <i>Frontiers in Cardiovascular Medicine</i> , 2020, 7, 51.	1.1	16
239	Neutrophil Extracellular Traps as Prognostic Markers in COVID-19. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2021, 41, 995-998.	1.1	16
240	Culprit site extracellular DNA and microvascular obstruction in ST-elevation myocardial infarction. <i>Cardiovascular Research</i> , 2022, 118, 2006-2017.	1.8	16
241	The Influence of Age on Human Pancreatic Growth Hormone Releasing Hormone Stimulated Growth Hormone Secretion. <i>Hormone and Metabolic Research</i> , 1988, 20, 574-578.	0.7	15
242	Randomized comparison between intracoronary 125 I-radiation brachytherapy and implantation of paclitaxel-eluting stents for the treatment of diffuse in-stent restenosis. <i>Radiotherapy and Oncology</i> , 2007, 82, 18-23.	0.3	15
243	Outcome after device implantation in chronic heart failure is dependent on concomitant medical treatment. <i>European Journal of Clinical Investigation</i> , 2009, 39, 1073-1081.	1.7	15
244	Strategic target temperature management in myocardial infarction—a feasibility trial. <i>Heart</i> , 2013, 99, 1663-1667.	1.2	15
245	Long-term outcome and risk assessment in premature acute myocardial infarction: A 10-year follow-up study. <i>International Journal of Cardiology</i> , 2017, 240, 37-42.	0.8	15
246	Disaggregation Following Agonist-Induced Platelet Activation in Patients on Dual Antiplatelet Therapy. <i>Journal of Cardiovascular Translational Research</i> , 2017, 10, 359-367.	1.1	15
247	Proteomics in Hypothermia as Adjunctive Therapy in Patients with ST-Segment Elevation Myocardial Infarction: A CHILL-MI Substudy. <i>Therapeutic Hypothermia and Temperature Management</i> , 2017, 7, 152-161.	0.3	15
248	Temporary treatment interruptions with oral selexipag in pulmonary arterial hypertension: Insights from the Prostacyclin (PGI ₂) Receptor Agonist in Pulmonary Arterial Hypertension (GRIPHON) study. <i>Journal of Heart and Lung Transplantation</i> , 2018, 37, 401-408.	0.3	15
249	2015 ESC/ERS GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF PULMONARY HYPERTENSION. <i>Russian Journal of Cardiology</i> , 2016, , 5-64.	0.4	15
250	Advanced Imaging Tools Rather Than Hemodynamics Should Be the Primary Approach for Diagnosing, Following, and Managing Pulmonary Arterial Hypertension. <i>Canadian Journal of Cardiology</i> , 2015, 31, 521-528.	0.8	14
251	Transcatheter aortic valve replacement (TAVR) leads to an increase in the subendocardial viability ratio assessed by pulse wave analysis. <i>PLoS ONE</i> , 2018, 13, e0207537.	1.1	14
252	Balloon pulmonary angioplasty for the treatment of chronic thromboembolic pulmonary hypertension: is Europe behind?. <i>European Respiratory Journal</i> , 2019, 53, 1900843.	3.1	14

#	ARTICLE	IF	CITATIONS
253	Adaptive development of concomitant secondary mitral and tricuspid regurgitation after transcatheter aortic valve replacement. <i>European Heart Journal Cardiovascular Imaging</i> , 2021, 22, 1045-1053.	0.5	14
254	Expression of Kunitz Protease Inhibitor-Containing Forms of Amyloid β -Protein Precursor Within Vascular Thrombi. <i>Circulation</i> , 1996, 94, 2728-2734.	1.6	14
255	Paediatric pulmonary vascular disease. <i>Paediatric Respiratory Reviews</i> , 2004, 5, 238-248.	1.2	13
256	2-Year Results of the AUTAX (Austrian Multivessel TAXUS-Stent) Registry. <i>JACC: Cardiovascular Interventions</i> , 2009, 2, 718-727.	1.1	13
257	Inhaled Iloprost for Patients With Precapillary Pulmonary Hypertension and Right-Side Heart Failure. <i>Journal of Cardiac Failure</i> , 2011, 17, 813-818.	0.7	13
258	An International Physician Survey of Pulmonary Arterial Hypertension Management. <i>Pulmonary Circulation</i> , 2016, 6, 338-346.	0.8	13
259	Impact of Right Ventricular Performance in Patients Undergoing Extracorporeal Membrane Oxygenation Following Cardiac Surgery. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	13
260	Multi-view approach for the diagnosis of pulmonary hypertension using transthoracic echocardiography. <i>International Journal of Cardiovascular Imaging</i> , 2017, 34, 695-700.	0.7	13
261	The impact of cardiopulmonary resuscitation (CPR) manikin chest stiffness on motivation and CPR performance measures in children undergoing CPR training- A prospective, randomized, single-blind, controlled trial. <i>PLoS ONE</i> , 2018, 13, e0202430.	1.1	13
262	Riociguat treatment in patients with pulmonary arterial hypertension: Final safety data from the EXPERT registry. <i>Respiratory Medicine</i> , 2021, 177, 106241.	1.3	13
263	The Adult Patient with Eisenmenger Syndrome: A Medical Update after Dana Point Part II: Medical Treatment - Study Results. <i>Current Cardiology Reviews</i> , 2010, 6, 356-362.	0.6	12
264	Advances in our understanding of mechanisms of venous thrombus resolution. <i>Expert Review of Hematology</i> , 2016, 9, 69-78.	1.0	12
265	Discriminatory power of scoring systems for outcome prediction in patients with extracorporeal membrane oxygenation following cardiovascular surgery-€. <i>European Journal of Cardio-thoracic Surgery</i> , 2019, 56, 534-540.	0.6	12
266	Pulmonary artery to ascending aorta ratio by echocardiography: A strong predictor for presence and severity of pulmonary hypertension. <i>PLoS ONE</i> , 2020, 15, e0235716.	1.1	12
267	Long-Term Survival, Safety and Tolerability with Selexipag in Patients with Pulmonary Arterial Hypertension: Results from GRIPHON and its Open-Label Extension. <i>Advances in Therapy</i> , 2022, 39, 796-810.	1.3	12
268	The Role of Treprostinil in the Management of Pulmonary Hypertension. <i>American Journal of Cardiovascular Drugs</i> , 2008, 8, 213-217.	1.0	11
269	High levels of platelet-monocyte aggregates after valve replacement for aortic stenosis: Relation to soluble P-selectin and P-selectin glycoprotein ligand-1 genes. <i>Thrombosis Research</i> , 2012, 129, 453-458.	0.8	11
270	Pro-oxidant HDL predicts poor outcome in patients with ST-elevation acute coronary syndrome. <i>Thrombosis and Haemostasis</i> , 2015, 114, 133-138.	1.8	11

#	ARTICLE	IF	CITATIONS
271	Mechanical properties of the everolimus-eluting bioresorbable vascular scaffold compared to the metallic everolimus-eluting stent. <i>BMC Cardiovascular Disorders</i> , 2016, 16, 104.	0.7	11
272	Safety and Efficacy of Polymer-Free Biolimus A9â€œCoated Versus Bare-Metal Stents in Orally Anticoagulated Patients. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 1633-1642.	1.1	11
273	Management and clinical outcome of stable coronary artery disease in Austria. <i>Wiener Klinische Wochenschrift</i> , 2017, 129, 879-892.	1.0	11
274	Altered structure and function of fibrinogen after cleavage by Factor VII Activating Protease (FSAP). <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2018, 1864, 3397-3406.	1.8	11
275	Rationale and design of the MULTISTARS AMI Trial: A randomized comparison of immediate versus staged complete revascularization in patients with ST-segment elevation myocardial infarction and multivessel disease. <i>American Heart Journal</i> , 2020, 228, 98-108.	1.2	11
276	Dyspnea after pulmonary embolism: a nationâ€œwide populationâ€œbased caseâ€œcontrol study. <i>Pulmonary Circulation</i> , 2021, 11, 1-9.	0.8	11
277	Small vessel stenting with cobaltâ€œchromium stents (Arthos Pico) in a real world setting. <i>Coronary Artery Disease</i> , 2007, 18, 305-311.	0.3	10
278	Costâ€œeffectiveness of percutaneous coronary intervention with drugâ€œeluting stents in patients with multivessel coronary artery disease compared to coronary artery bypass surgery fiveâ€œyears after intervention. <i>Catheterization and Cardiovascular Interventions</i> , 2014, 84, 1029-1039.	0.7	10
279	Peri-interventional endothelin-A receptor blockade improves long-term outcome in patients with ST-elevation acute myocardial infarction. <i>Thrombosis and Haemostasis</i> , 2014, 112, 176-182.	1.8	10
280	Normal values for Doppler echocardiographic assessment of prosthetic valve function after transcatheter aortic valve replacement: a systematic review and meta-analysis. <i>European Heart Journal Cardiovascular Imaging</i> , 2018, 19, 361-368.	0.5	10
281	Predictive Value of High-Sensitivity Troponin T for Systolic Dysfunction and Infarct Size (Six Months) After ST-Elevation Myocardial Infarction. <i>American Journal of Cardiology</i> , 2018, 122, 735-743.	0.7	10
282	Using proximity extension proteomics assay to identify biomarkers associated with infarct size and ejection fraction after ST-elevation myocardial infarction. <i>Scientific Reports</i> , 2020, 10, 18663.	1.6	10
283	Anticoagulation use and the risk of stroke and major bleeding in patients on hemodialysis: From the VIVALDI, a populationâ€œbased prospective cohort study. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 2984-2996.	1.9	10
284	The use of fluorescence correlation spectroscopy (FCS) as an alternative biomarker detection technique: a preliminary study. <i>Journal of Cellular and Molecular Medicine</i> , 2011, 15, 2706-2711.	1.6	9
285	Proteomic profiling of acute coronary thrombosis reveals a local decrease in pigment epithelium-derived factor in acute myocardial infarction. <i>Clinical Science</i> , 2012, 123, 111-119.	1.8	9
286	Dabigatran after Short Heparin Anticoagulation for Acute Intermediate-Risk Pulmonary Embolism: Rationale and Design of the Single-Arm PEITHO-2 Study. <i>Thrombosis and Haemostasis</i> , 2017, 117, 2425-2434.	1.8	9
287	Polyunsaturated fatty acids supplementation impairs antiâ€œoxidant highâ€œdensity lipoprotein function in heart failure. <i>European Journal of Clinical Investigation</i> , 2018, 48, e12998.	1.7	9
288	von Willebrand Factor Predicts Mortality in ACS Patients Treated with Potent P2Y12 Antagonists and is Inhibited by Aptamer BT200 Ex Vivo. <i>Thrombosis and Haemostasis</i> , 2020, 120, 1282-1290.	1.8	9

#	ARTICLE	IF	CITATIONS
289	Neutrophil Extracellular Traps in Atherosclerosis and Thrombosis. Handbook of Experimental Pharmacology, 2020, , 405-425.	0.9	9
290	Plasma Trimethylamine-N-Oxide Is an Independent Predictor of Long-Term Cardiovascular Mortality in Patients Undergoing Percutaneous Coronary Intervention for Acute Coronary Syndrome. Frontiers in Cardiovascular Medicine, 2021, 8, 728724.	1.1	9
291	Purification of Storage Granule Protein-23. Journal of Biological Chemistry, 1996, 271, 30126-30135.	1.6	8
292	Increased intimal apoptosis in coronary atherosclerotic vessel segments lacking compensatory enlargement. Journal of the American College of Cardiology, 2001, 38, 1333-1339.	1.2	8
293	Non-invasive algorithms for the diagnosis of pulmonary hypertension. Thrombosis and Haemostasis, 2012, 108, 1037-1041.	1.8	8
294	Gender-related impact on outcomes of high density lipoprotein in acute ST-elevation myocardial infarction. Atherosclerosis, 2016, 251, 460-466.	0.4	8
295	Acetylsalicylic acid in critically ill patients: a cross-sectional and a randomized trial. European Journal of Clinical Investigation, 2017, 47, 504-512.	1.7	8
296	Endothelial cells from pulmonary endarterectomy specimens possess a high angiogenic potential and express high levels of hepatocyte growth factor. BMC Pulmonary Medicine, 2018, 18, 197.	0.8	8
297	Interdependence of VA-ECMO output, pulmonary congestion and outcome after cardiac surgery. European Journal of Internal Medicine, 2020, 81, 67-70.	1.0	8
298	Impaired High-Density Lipoprotein Anti-Oxidant Function Predicts Poor Outcome in Critically Ill Patients. PLoS ONE, 2016, 11, e0151706.	1.1	8
299	Hereditary Hemorrhagic Telangiectasia and Pregnancy. Obstetrics and Gynecology, 2007, 110, 474-477.	1.2	7
300	Long-term outcome after thrombectomy in acute myocardial infarction. European Journal of Clinical Investigation, 2010, 40, 233-241.	1.7	7
301	Pulmonary hypertension: chapters of innovation and tribulation. European Heart Journal, 2012, 33, 961-968.	1.0	7
302	Hypoxia/reperfusion predisposes to atherosclerosis. PLoS ONE, 2018, 13, e0205067.	1.1	7
303	Coronary interventions in Austria, Germany, and Switzerland. European Heart Journal, 2020, 41, 2599-2600.	1.0	7
304	Impact of treatment strategies on long-term outcome of CTO patients. European Journal of Internal Medicine, 2020, 77, 97-104.	1.0	7
305	Deoxyribonuclease 1 Q222R single nucleotide polymorphism and long-term mortality after acute myocardial infarction. Basic Research in Cardiology, 2021, 116, 29.	2.5	7
306	Randomized blinded clinical trial of intracoronary brachytherapy with ⁹⁰ Sr/Y beta-radiation for the prevention of restenosis after stent implantation in native coronary arteries in diabetic patients. Radiotherapy and Oncology, 2006, 78, 60-66.	0.3	6

#	ARTICLE	IF	CITATIONS
307	Update on Chronic Thromboembolic Pulmonary Hypertension, a Frequently Undiagnosed Condition. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2009, 62, 120-125.	0.4	6
308	Exhaled nitric oxide measurement to monitor pulmonary hypertension in a pneumonectomy-monocrotaline rat model. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2013, 305, L485-L490.	1.3	6
309	Interdependence between osteoprotegerin and active von Willebrand factor in long-term cardiovascular mortality prediction in patients undergoing percutaneous coronary intervention. <i>Thrombosis and Haemostasis</i> , 2017, 117, 1730-1738.	1.8	6
310	9-year clinical follow-up of patients with ST-segment elevation myocardial infarction with Genous or TAXUS LibertÃ© stents. <i>PLoS ONE</i> , 2018, 13, e0201416.	1.1	6
311	Echocardiographic evaluation of left ventricular filling pressures in patients with pulmonary hypertension. <i>International Journal of Cardiovascular Imaging</i> , 2019, 35, 861-868.	0.7	6
312	Right atrial strain is a surrogate of coupling in the right heart. <i>European Heart Journal Cardiovascular Imaging</i> , 2020, 21, 863-864.	0.5	6
313	Pulmonary Artery Endovascular Device Compensates for Loss of Vascular Compliance in Pulmonary Arterial Hypertension. <i>Journal of the American College of Cardiology</i> , 2020, 76, 2284-2286.	1.2	6
314	Ticagrelor and prasugrel are independent predictors of improved long-term survival in ACS patients. <i>European Journal of Clinical Investigation</i> , 2020, 50, e13304.	1.7	6
315	Balloon pulmonary angioplasty for the treatment of chronic thromboembolic pulmonary hypertension. <i>EuroIntervention</i> , 2019, 15, e814-e815.	1.4	6
316	Causes of death in early MI survivors with persistent infarct artery occlusion: results from the Occluded Artery Trial (OAT). <i>EuroIntervention</i> , 2009, 5, 610-618.	1.4	6
317	EGR1 Is Implicated in Right Ventricular Cardiac Remodeling Associated with Pulmonary Hypertension. <i>Biology</i> , 2022, 11, 677.	1.3	6
318	Processing of autologous bone marrow cells by apheresis technology for cell-based cardiovascular regeneration. <i>Cytotherapy</i> , 2012, 14, 1005-1010.	0.3	5
319	Association of Thrombin Generation Potential with Platelet PAR-1 Regulation and P-Selectin Expression in Patients on Dual Antiplatelet Therapy. <i>Journal of Cardiovascular Translational Research</i> , 2014, 7, 126-132.	1.1	5
320	Treating pulmonary hypertension in the elderly. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 1193-1200.	0.9	5
321	Impact of sex on the management and outcome of aortic stenosis patients: a female aortic valve stenosis paradox, and a call for personalized treatments?. <i>European Heart Journal</i> , 2021, 42, 2692-2694.	1.0	5
322	Cerebral Protection in TAVRâ€”Can We Do Without? A Real-World All-Corner Intention-to-Treat Studyâ€”Impact on Stroke Rate, Length of Hospital Stay, and Twelve-Month Mortality. <i>Journal of Personalized Medicine</i> , 2022, 12, 320.	1.1	5
323	Pulmonary Veno-occlusive Disease in a Patient with Unilateral Absence of Right Pulmonary Artery. <i>Chest</i> , 1988, 93, 1307-1309.	0.4	4
324	Short- and long-term clinical outcome after various stent implantation: Overview of the results of uni- and multicenter stent registries. <i>Catheterization and Cardiovascular Interventions</i> , 2004, 62, 331-338.	0.7	4

#	ARTICLE	IF	CITATIONS
325	Human platelet protease-activated receptor-1 responsiveness to thrombin related to P2Y12 inhibition. <i>Translational Research</i> , 2013, 161, 414-420.	2.2	4
326	Effects of endothelin A receptor blockade in patients with ST-elevation acute coronary syndrome – A rhythmologic substudy. <i>Life Sciences</i> , 2014, 118, 430-434.	2.0	4
327	Clinical presentation and management of stable coronary artery disease in Austria. <i>PLoS ONE</i> , 2017, 12, e0176257.	1.1	4
328	Ranolazine: impact on quality of life in patients with stable angina pectoris, results from an observational study in Austria – the ARETHA study. <i>Wiener Klinische Wochenschrift</i> , 2019, 131, 165-173.	1.0	4
329	What is new in the 2018 ESC guidelines for the management of cardiovascular diseases during pregnancy?. <i>Wiener Klinische Wochenschrift</i> , 2020, 132, 69-72.	1.0	4
330	High Platelet Reactivity after Transition from Cangrelor to Ticagrelor in Hypothermic Cardiac Arrest Survivors with ST-Segment Elevation Myocardial Infarction. <i>Journal of Clinical Medicine</i> , 2020, 9, 583.	1.0	4
331	Comparison of Light Transmission Aggregometry With Impedance Aggregometry in Patients on Potent P2Y12 Inhibitors. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2021, 26, 260-268.	1.0	4
332	Risk Factors for Chronic Thromboembolic Pulmonary Hypertension. , 2011, , 1253-1259.		4
333	Long-Term Outcome of Combined (Percutaneous Intramyocardial and Intracoronary) Application of Autologous Bone Marrow Mononuclear Cells Post Myocardial Infarction: The 5-Year MYSTAR Study. <i>PLoS ONE</i> , 2016, 11, e0164908.	1.1	4
334	Abstract 2305: Pulmonary Vascular Reactivity And Prognosis In Patients With Chronic Thromboembolic Pulmonary Hypertension. <i>Circulation</i> , 2007, 116, .	1.6	4
335	Three-Dimensional Visualization of Pulmonary Thromboemboli in Chronic Thromboembolic Pulmonary Hypertension With Multiple Detector-Row Spiral Computed Tomography. <i>Circulation</i> , 2001, 103, 2993-2993.	1.6	3
336	Increased release of serotonin from rat ileum due to dexfenfluramine. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2004, 287, R1209-R1213.	0.9	3
337	Management of acute and chronic RV dysfunction. <i>Country Review Ukraine</i> , 2007, 9, H61-H67.	0.8	3
338	Treatment of pulmonary hypertension: bench to bedside. <i>Respiratory Medicine</i> , 2011, 105, S7-S11.	1.3	3
339	High-shear- and-thrombin-inducible platelet adhesion and aggregation in patients undergoing percutaneous coronary intervention. <i>Thrombosis and Haemostasis</i> , 2011, 105, 496-500.	1.8	3
340	Target vessel reopening by guidewire insertion in ST-elevation myocardial infarction is a predictor of final TIMI flow and survival. <i>Thrombosis and Haemostasis</i> , 2011, 105, 52-58.	1.8	3
341	Association between the rs342293 polymorphism and adverse cardiac events in patients undergoing percutaneous coronary intervention. <i>Thrombosis and Haemostasis</i> , 2014, 111, 1060-1066.	1.8	3
342	Measuring vasoreactivity in pulmonary hypertension: A simple test, but do we understand it?. <i>Journal of Heart and Lung Transplantation</i> , 2015, 34, 306-307.	0.3	3

#	ARTICLE	IF	CITATIONS
343	Diastolic Pulmonary Artery to Pulmonary Capillary Wedge Pressure Difference: A Predictor of Outcome After Left Ventricular Assist Device Implantation. <i>Journal of the American Heart Association</i> , 2020, 9, e016110.	1.6	3
344	The Roles of S100A4 and the EGF/EGFR Signaling Axis in Pulmonary Hypertension with Right Ventricular Hypertrophy. <i>Biology</i> , 2022, 11, 118.	1.3	3
345	A Real World 10-Year Experience With Vascular Closure Devices and Large-Bore Access in Patients Undergoing Transfemoral Transcatheter Aortic Valve Implantation. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 791693.	1.1	3
346	More Evidence for Inflammatory Thrombosis in Chronic Thromboembolic Pulmonary Hypertension: Is the Embolic Hypothesis Losing Ground?. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, 205, 745-746.	2.5	3
347	Dilatation of the Pulmonary Arteries in Primary Pulmonary Hypertension. <i>New England Journal of Medicine</i> , 1996, 334, 302-302.	13.9	2
348	Title is missing!. <i>Molecular and Cellular Biochemistry</i> , 2003, 249, 39-43.	1.4	2
349	Intracoronary brachytherapy with γ -radiation for the treatment of long diffuse in-stent restenosis. <i>Coronary Artery Disease</i> , 2004, 15, 285-289.	0.3	2
350	Extended-release oral treprostinil for the treatment of pulmonary arterial hypertension. <i>Expert Review of Cardiovascular Therapy</i> , 2014, 12, 1391-1399.	0.6	2
351	Changing perceptions in pulmonary hypertension. <i>Lancet Respiratory Medicine</i> , 2014, 2, 21-23.	5.2	2
352	Choriocarcinoma mimicking chronic thromboembolic pulmonary hypertension. <i>European Heart Journal</i> , 2016, 37, 1480-1480.	1.0	2
353	Delayed coronary obstruction following Portico in Freedom Solo valve-in-valve implantation. <i>Coronary Artery Disease</i> , 2017, 28, 528-529.	0.3	2
354	Chronic Thromboembolic Pulmonary Hypertension and Antiphospholipid Syndrome with Immune Thrombocytopenia: A Case Report. <i>American Journal of Case Reports</i> , 2018, 19, 1245-1248.	0.3	2
355	The Long-Term Impact of Post-Procedural Asymmetry and Eccentricity of Bioresorbable Everolimus-Eluting Scaffold and Metallic Everolimus-Eluting Stent on Clinical Outcomes in the ABSORB II Trial. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 1013-1015.	1.1	2
356	What is new in the 2017 ESC clinical practice guidelines. <i>Wiener Klinische Wochenschrift</i> , 2018, 130, 421-426.	1.0	2
357	Balloon pulmonary angioplasty for the treatment of chronic thromboembolic pulmonary hypertension: is Europe behind?. <i>European Respiratory Journal</i> , 2019, 54, 1901639.	3.1	2
358	Functional status and life satisfaction of patients with stable angina pectoris in Austria. <i>BMJ Open</i> , 2019, 9, e029661.	0.8	2
359	A multiparametric approach for the assessment of prognosis in pulmonary hypertension after pulmonary endarterectomy - stratifying risk in a poorly-defined condition. <i>International Journal of Cardiology</i> , 2021, 337, 101-102.	0.8	2
360	Results From the United States Chronic Thromboembolic Pulmonary Hypertension Registry. <i>Chest</i> , 2021, 160, 1599-1601.	0.4	2

#	ARTICLE	IF	CITATIONS
361	FOCUS on sequelae of acute pulmonary embolism: does it pay off?. <i>European Heart Journal</i> , 2022, 43, 3399-3401.	1.0	2
362	Levels of sCD40, sCD40L, TNF α , and TNF-RI in the Culprit Coronary Artery During Myocardial Infarction. <i>Laboratory Medicine</i> , 2009, 40, 660-664.	0.8	1
363	Chronic Thromboembolic Pulmonary Hypertension. <i>Progress in Respiratory Research</i> , 2012, , 226-236.	0.1	1
364	Research update for articles published in EJCI in 2010. <i>European Journal of Clinical Investigation</i> , 2012, 42, 1149-1164.	1.7	1
365	The VKORC1 polymorphism rs9923231 is associated with aneurysms of the ascending aorta in an Austrian population. <i>Thrombosis Research</i> , 2017, 152, 41-43.	0.8	1
366	Pulmonary Hypertension Due to Left Heart Disease. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2017, 38, 662-676.	0.8	1
367	Targeting inflammation and immunity in pulmonary arterial hypertension: any easier after the CANTOS proof-of-concept that anti-inflammation cuts cardiovascular events?. <i>Pulmonary Circulation</i> , 2018, 8, 1-3.	0.8	1
368	Focused Update on Pulmonary Hypertension in Children—Selected Topics of Interest for the Adult Cardiologist. <i>Medicina (Lithuania)</i> , 2020, 56, 420.	0.8	1
369	Synthetic Fibrin-Derived B β 15-42 Peptide Delays Thrombus Resolution in a Mouse Model. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2021, 41, 2168-2180.	1.1	1
370	Deoxyribonuclease is prognostic in patients undergoing transcatheter aortic valve replacement. <i>European Journal of Clinical Investigation</i> , 2021, 51, e13595.	1.7	1
371	Clinical Impact of Pre-Procedural Percutaneous Coronary Intervention in Low- and Intermediate-Risk Transcatheter Aortic Valve Replacement Recipients. <i>Journal of Personalized Medicine</i> , 2021, 11, 633.	1.1	1
372	Mild Therapeutic Hypothermia Alters Hemostasis in ST Elevation Myocardial Infarction Patients. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 707367.	1.1	1
373	Copeptin Levels Are Independent from Mild Therapeutic Hypothermia but Do Not Predict Infarct Size in Patients Presenting with ST-Segment Elevation Myocardial Infarction. <i>Journal of Cardiovascular Development and Disease</i> , 2021, 8, 131.	0.8	1
374	Chronic thromboembolic pulmonary hypertension. , 2012, , 108-118.		1
375	Pulmonary Endothelium in Thromboembolism. , 0, , 471-483.		1
376	Cardiovascular management. <i>BMJ: British Medical Journal</i> , 2003, 326, 1135-1136.	2.4	0
377	The Austrian Multivessel Taxus σ Stent (AUTAX) registry. <i>Interventional Cardiology</i> , 2010, 2, 113-120.	0.0	0
378	Chronic thromboembolic pulmonary hypertension (CTEPH): specific disease characteristics and similarities to idiopathic pulmonary arterial hypertension. <i>Clinical Research in Cardiology Supplements</i> , 2010, 5, 12-15.	2.0	0

#	ARTICLE	IF	CITATIONS
379	Pulmonale Hypertension. Wiener Klinische Wochenschrift Education, 2011, 6, 78-93.	0.0	0
380	New developments in the treatment of chronic thromboembolic pulmonary hypertension. Clinical Investigation, 2012, 2, 397-402.	0.0	0
381	Thrombosis – Besieged but Poorly Understood. Frontiers in Cardiovascular Medicine, 2014, 1, 4.	1.1	0
382	Restenosis after coronary spasm in a bioresorbable vascular scaffold. Coronary Artery Disease, 2016, 27, 159-161.	0.3	0
383	Selexipag, an orally available IP receptor agonist, in the treatment of pulmonary arterial hypertension: current evidence and future prospects. Expert Opinion on Orphan Drugs, 2017, 5, 193-200.	0.5	0
384	The aureole sign: a rare echocardiographic artefact. European Heart Journal Cardiovascular Imaging, 2017, 18, 722-722.	0.5	0
385	The Pulmonary Vascular Research Institute celebrates its first decade. Pulmonary Circulation, 2017, 7, 283-284.	0.8	0
386	Pulmonary hypertension associated with left heart disease: efforts to improve the meaning of haemodynamic phenotypes. European Respiratory Journal, 2019, 53, 1802393.	3.1	0
387	Diffusion capacity of the lung – a disease biomarker linking ventilation and circulation. Journal of Heart and Lung Transplantation, 2019, 38, 130-132.	0.3	0
388	Computer modeling to predict balloon pulmonary angioplasty success. American Journal of Physiology - Heart and Circulatory Physiology, 2021, 321, H567-H568.	1.5	0
389	Coagulation and the Vessel Wall in Pulmonary Embolism. , 2011, , 851-860.		0
390	Chronic thromboembolic pulmonary hypertension. , 2011, , 528-537.		0
391	The Right Heart in Chronic Thromboembolic Pulmonary Hypertension. , 2014, , 243-257.		0
392	The Role of Neutrophil Extracellular Traps in Cancer-Associated Arterial Thrombosis. Blood, 2018, 132, 2508-2508.	0.6	0
393	Isolated Postcapillary and Combined Pre- and Postcapillary Pulmonary Hypertension. Respiratory Medicine, 2020, , 61-70.	0.1	0
394	New ECG algorithms with improved accuracy for prediction of culprit vessel in inferior ST-Segment elevation myocardial infarction. Panminerva Medica, 2021, , .	0.2	0
395	Balloon Pulmonary Angioplasty for Inoperable Chronic Thromboembolic Pulmonary Hypertension: First Experience at the Israeli National CTEPH Referral Center. Israel Medical Association Journal, 2020, 22, 752-756.	0.1	0
396	Larger pulmonary artery to ascending aorta ratios are associated with decreased survival of patients undergoing pulmonary endarterectomy. JTCVS Open, 2022, , .	0.2	0

#	ARTICLE	IF	CITATIONS
397	High concentration of symmetric dimethylarginine is associated with low platelet reactivity and increased bleeding risk in patients with acute coronary syndrome. <i>Thrombosis Research</i> , 2022, 213, 195-202.	0.8	0